321 related articles for article (PubMed ID: 10673793)
1. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
Migliari R; Muscas G; Murru M; Verdacchi T; De Benedetto G; De Angelis M
Arch Ital Urol Androl; 1999 Dec; 71(5):293-302. PubMed ID: 10673793
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.
Mahler C; Verhelst J; Denis L
Clin Pharmacokinet; 1998 May; 34(5):405-17. PubMed ID: 9592622
[TBL] [Abstract][Full Text] [Related]
3. Antiandrogens as monotherapy for prostate cancer.
Schröder FH
Eur Urol; 1998; 34 Suppl 3():12-7. PubMed ID: 9854190
[TBL] [Abstract][Full Text] [Related]
4. Antiandrogen monotherapy in the management of advanced prostate cancer.
Kaisary AV
Eur Urol; 1997; 31 Suppl 2():14-9; discussion 24-7. PubMed ID: 9074906
[TBL] [Abstract][Full Text] [Related]
5. The role of antiandrogen monotherapy in the treatment of prostate cancer.
Anderson J
BJU Int; 2003 Mar; 91(5):455-61. PubMed ID: 12603397
[TBL] [Abstract][Full Text] [Related]
6. Nilutamide: an antiandrogen for the treatment of prostate cancer.
Dole EJ; Holdsworth MT
Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
[TBL] [Abstract][Full Text] [Related]
7. Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma.
Schröder FH
Prog Clin Biol Res; 1990; 359():93-103; discussion 105-7. PubMed ID: 2149460
[TBL] [Abstract][Full Text] [Related]
8. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.
Sciarra A; Cardi A; Di Silverio F
Urol Int; 2004; 72(2):91-8. PubMed ID: 14963347
[TBL] [Abstract][Full Text] [Related]
9. [Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications].
Akakura K; Furuya Y; Ito H
Nihon Rinsho; 1998 Aug; 56(8):2124-8. PubMed ID: 9750520
[TBL] [Abstract][Full Text] [Related]
10. Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen.
Sarosdy MF
Anticancer Drugs; 1999 Oct; 10(9):791-6. PubMed ID: 10587288
[TBL] [Abstract][Full Text] [Related]
11. "Casodex" (ICI 176,334)--a new, pure, peripherally-selective anti-androgen: preclinical studies.
Furr BJ
Horm Res; 1989; 32 Suppl 1():69-76. PubMed ID: 2533159
[TBL] [Abstract][Full Text] [Related]
12. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
13. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
[TBL] [Abstract][Full Text] [Related]
14. Antiandrogen treatments in locally advanced prostate cancer: are they all the same?
Gillatt D
J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S17-26. PubMed ID: 16845534
[TBL] [Abstract][Full Text] [Related]
15. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
Furr BJ; Tucker H
Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
[TBL] [Abstract][Full Text] [Related]
16. Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer?
Boccon-Gibod L
Eur Urol; 1998; 33(2):159-64. PubMed ID: 9519357
[TBL] [Abstract][Full Text] [Related]
17. Antiandrogenic drugs.
McLeod DG
Cancer; 1993 Feb; 71(3 Suppl):1046-9. PubMed ID: 8428326
[TBL] [Abstract][Full Text] [Related]
18. Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer.
Kolvenbag GJ; Iversen P; Newling DW
Urology; 2001 Aug; 58(2 Suppl 1):16-23. PubMed ID: 11502439
[TBL] [Abstract][Full Text] [Related]
19. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Blackledge G; Kolvenbag G; Nash A
Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
[TBL] [Abstract][Full Text] [Related]
20. [The role of bicalutamide in the treatment of prostate cancer].
Stav SY; Segal G
Harefuah; 2002 Apr; 141(4):379-83, 408, 407. PubMed ID: 12017896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
